NZ507901A - Isolated myelin basic protein (MBP) for treating mutliple sclerosis - Google Patents
Isolated myelin basic protein (MBP) for treating mutliple sclerosisInfo
- Publication number
- NZ507901A NZ507901A NZ507901A NZ50790199A NZ507901A NZ 507901 A NZ507901 A NZ 507901A NZ 507901 A NZ507901 A NZ 507901A NZ 50790199 A NZ50790199 A NZ 50790199A NZ 507901 A NZ507901 A NZ 507901A
- Authority
- NZ
- New Zealand
- Prior art keywords
- basic protein
- myelin basic
- thr
- phe
- ile
- Prior art date
Links
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 title abstract 4
- 208000034189 Sclerosis Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000043131 MHC class II family Human genes 0.000 abstract 2
- 108091054438 MHC class II family Proteins 0.000 abstract 2
- 102000047918 Myelin Basic Human genes 0.000 abstract 2
- 101710107068 Myelin basic protein Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000035479 physiological effects, processes and functions Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rehabilitation Therapy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A myelin basic protein (MBP) peptide has an amino acid sequence of Phe-X-Lys-Asn-Ile-Val-X-X-X-Thr-X-X, wherein X is any amino acid. Preferably the sequence is Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-Pro. Also described are antibodies and a composition comprising an MHC Class II complex, capable of binding a T cell receptor, and a myelin basic protein peptide of the sequence Phe-X-Lys-R1-Ile-Val-X-X-X-Thr-X-X, wherein X is any amino acid and R1 is Asn or Gln. The complex consists of An MHC Class II polypeptide comprising an extracellular domain of an MHC Class II molecule sufficient to form an antigen binding pocket wherein the Class II component is encoded by an allele associated with an autoimmune disease directed to myelin basic protein and is soluble under physiology conditions in the absence of detergent or lipid. The composition and the peptide are useful in inhibiting a T-cell mediated immune response, preferably wherein the T-cell mediated immune response causes a pathology to the a neurological system i.e. multiple sclerosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7310998A | 1998-05-05 | 1998-05-05 | |
| PCT/US1999/009930 WO1999057241A2 (en) | 1998-05-05 | 1999-05-05 | Myelin basic protein peptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ507901A true NZ507901A (en) | 2003-06-30 |
Family
ID=22111789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ507901A NZ507901A (en) | 1998-05-05 | 1999-05-05 | Isolated myelin basic protein (MBP) for treating mutliple sclerosis |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1080185A4 (en) |
| JP (1) | JP2002513558A (en) |
| CN (1) | CN1308671A (en) |
| AU (1) | AU3789099A (en) |
| CA (1) | CA2330826A1 (en) |
| HK (1) | HK1039636A1 (en) |
| NO (1) | NO20005547L (en) |
| NZ (1) | NZ507901A (en) |
| WO (1) | WO1999057241A2 (en) |
| ZA (1) | ZA200006268B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4538192B2 (en) * | 2001-05-01 | 2010-09-08 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Fusion molecules and methods for treating immune disorders |
| US7265208B2 (en) | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
| ITFI20010114A1 (en) * | 2001-06-22 | 2002-12-22 | Univ Firenze | GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE IN THE DIAGNOSIS OR THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS |
| DK2227486T3 (en) * | 2007-11-20 | 2017-06-19 | Vianex S A | Peptide Analogs and Conjugates Thereby |
| JPWO2016159181A1 (en) * | 2015-03-30 | 2018-02-22 | 国立大学法人大阪大学 | Peptide for immunization, method for producing immunity peptide, pharmaceutical composition for immune disease including the same, and method for treating immune disease |
| JP2022536797A (en) * | 2019-06-18 | 2022-08-18 | ザ スクリプス リサーチ インスティテュート | Methods and compositions for treating inflammatory conditions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
| WO1996012737A2 (en) * | 1994-10-25 | 1996-05-02 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| WO1996040944A2 (en) * | 1995-06-07 | 1996-12-19 | Zymogenetics, Inc. | Fused soluble mhc heterodimer:peptide complexes and their uses |
-
1999
- 1999-05-05 WO PCT/US1999/009930 patent/WO1999057241A2/en not_active Ceased
- 1999-05-05 AU AU37890/99A patent/AU3789099A/en not_active Abandoned
- 1999-05-05 CA CA002330826A patent/CA2330826A1/en not_active Abandoned
- 1999-05-05 CN CN99808248A patent/CN1308671A/en active Pending
- 1999-05-05 NZ NZ507901A patent/NZ507901A/en unknown
- 1999-05-05 EP EP99920379A patent/EP1080185A4/en not_active Withdrawn
- 1999-05-05 JP JP2000547197A patent/JP2002513558A/en active Pending
- 1999-05-05 HK HK02101092.3A patent/HK1039636A1/en unknown
-
2000
- 2000-11-02 ZA ZA200006268A patent/ZA200006268B/en unknown
- 2000-11-03 NO NO20005547A patent/NO20005547L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20005547D0 (en) | 2000-11-03 |
| CA2330826A1 (en) | 1999-11-11 |
| AU3789099A (en) | 1999-11-23 |
| NO20005547L (en) | 2001-01-02 |
| JP2002513558A (en) | 2002-05-14 |
| EP1080185A2 (en) | 2001-03-07 |
| CN1308671A (en) | 2001-08-15 |
| WO1999057241A3 (en) | 2000-01-13 |
| EP1080185A4 (en) | 2005-01-26 |
| ZA200006268B (en) | 2001-08-22 |
| WO1999057241A9 (en) | 2000-02-17 |
| WO1999057241A2 (en) | 1999-11-11 |
| HK1039636A1 (en) | 2002-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Salter et al. | A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2 | |
| Born et al. | Recognition of a peptide antigen by heat shock--reactive γδ T lymphocytes | |
| EP0997477A3 (en) | MHC complexes and uses thereof | |
| Beisiegel et al. | The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein | |
| Lobb et al. | Immunoglobulin light chain classes in a teleost fish. | |
| Harding et al. | Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation | |
| Accolla et al. | Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool. | |
| EP1526141A3 (en) | MHC complexes and uses thereof | |
| Lanier | Natural killer cell receptors and MHC class I interactions | |
| ATE415173T1 (en) | PAN DR BINDING PROTEINS TO INCREASE THE IMMUNE RESPONSE | |
| CA2290485A1 (en) | Method for the production of non-immunogenic proteins | |
| EP0340793A3 (en) | Endowing cells with antibody specificity | |
| IL142905A0 (en) | Functional antagonists of hedgehog activity | |
| DE69435261D1 (en) | HUMAN RECIPE H4-1BB | |
| AU6726698A (en) | Use of interleukin-15 | |
| Haber et al. | Specificity of antigenic recognition of antibody heavy chain | |
| CA2248667A1 (en) | Hla-a2.1 binding peptides and their uses | |
| CA2296737A1 (en) | Ligand for herpes simplex virus entry mediator and methods of use | |
| Aichinger et al. | Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins | |
| EP0820469A4 (en) | Identification, purification and uses of leczymes and carbohydrate ligands | |
| NZ507901A (en) | Isolated myelin basic protein (MBP) for treating mutliple sclerosis | |
| Johnson et al. | A novel arginine vasopressin-binding peptide that blocks arginine vasopressin modulation of immune function. | |
| GR3030152T3 (en) | A human t-cell receptor of the g-protein coupled receptor family | |
| Moustakas et al. | Molecular properties of HLA‐DQ alleles conferring susceptibility to or protection from insulin‐dependent diabetes mellitus: Keys to the fate of islet β‐cells | |
| Cresswell | Antigen recognition by T lymphocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |